Abbott (NYSE:ABT) announced today that a new study supports the use of its FreeStyle Libre 2 continuous glucose monitor (CGM). The study, published in The New England Journal of Medicine, evaluated adults with type 1 diabetes and suboptimal glycemic control. It demonstrated significant reductions in glycated hemoglobin (HbA1c) compared to self-monitoring of blood glucose. Subjects […]
Patient Monitoring
Published data backs digital therapeutic for diabetes from Better Therapeutics
Better Therapeutics (Nasdaq:BTTX) announced today that newly published data supports its digital therapeutic for type 2 diabetes. San Francisco-based Better Therapeutics develops the BT-001 prescription digital therapeutic (PDT). It potentially represents the first-in-class PDT using cognitive behavioral therapy (CBT) to treat type 2 diabetes. In July, the company completed the pivotal trial for its BT-001 digital therapeutic […]
Dexcom G7 launches in a handful of countries outside the U.S.
Dexcom (Nasdaq:DXCM) announced today that it made the next-generation Dexcom G7 available in a number of countries outside the U.S. The San Diego-based company now offers Dexcom G7 in the UK, Ireland, Germany, Austria and Hong Kong. Availability covers people with diabetes aged two years and older. The launch marks the first major milestone in […]
Sensoria Health and Defender launch smart boot for diabetics
Sensoria Health and Defender announced today that they launched the Foot Defender powered by Sensoria smart boot. The companies say the boot marks the world’s first smart diabetic footwear. It helps heal diabetic foot ulcers and reduces the risk of amputations for extended quality of life. In a news release, they said the solution combines […]
7 innovative digital health offerings to treat diabetes
From using your smartphone to track data to reversing your diabetes altogether, these digital health technologies stand out. Advances in treatments for diabetes never stop coming. Whether that be in the form of insulin pumps or continuous glucose monitors, we’ve seen plenty. Moving away from the physical device, innovations in the digital diabetes space continue […]
Study backs automated insulin delivery system from Diabeloop
Diabeloop today announced 12-month data supporting its hybrid closed-loop DBLG1 automated insulin delivery system. Paris-based Diabeloop evaluated DBLG1 in a large, multi-country patient cohort. Results demonstrated constant improvement in time in range and time in hypoglycemia remaining significantly low. The company said in a news release that the results, combined with trust in its algorithm, […]
Study says Abbott FreeStyle Libre reduces rate of hospitalization
Abbott (NYSE:ABT) today announce real-world data demonstrating reductions in hospitalizations associated with the FreeStyle Libre system. The RELIEF study evaluated Abbott’s FreeStyle Libre continuous glucose monitoring (CGM). The findings included the significant reduction of the rate of hospitalizations due to acute diabetes events (ADEs). This study evaluated people living with type 2 diabetes on once-daily […]
Insulet wins CE Mark for Omnipod 5 for children 2 and up
Insulet (Nasdaq:PODD) announced today that it received CE mark approval in Europe for its Omnipod 5 automated insulin delivery system. Insulet can now market Omnipod 5 in Europe for individuals 2 years and older with type 1 diabetes. Acton, Massachusetts-based Insulet said it represents the first CE-marked tubeless hybrid closed loop system. The latest-generation Omnipod 5 […]
Senseonics CFO is leaving
Senseonics (NYSE:SENS) announced that its chief financial officer, Nick Tressler, is transitioning from his position at the CMG company.. Tressler’s transition is effective as of yesterday, Sept. 1, 2022. Senseonics selected VP of Finance, Rick Sullivan, to succeed Tressler as CFO. In an effort to ensure an orderly change, Tressler will remain with the company […]
Study backs next-gen Medtronic MiniMed 780G insulin pump
Medtronic (NYSE:MDT) today announced positive results from a study of its next-generation MiniMed 780G automated insulin delivery system. Results from the ADAPT study, published in The Lancet Diabetes & Endocrinology, demonstrated improved glycemic control and treatment satisfaction among users of MiniMed 780G. The MiniMed 780G system is available in more than 60 countries. It is currently […]
